Thank you to all our sponsors and partners for their support and for contributing to the success of the Geneva edition.
2022 World Cancer Congress
IN COOPERATION WITH
World Health Organization (WHO)
Founded in 1948, WHO is the United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health. WHO leads global efforts to expand universal health coverage. We direct and coordinate the world’s response to health emergencies. And we promote healthier lives – from pregnancy care through old age. Our Triple Billion targets outline an ambitious plan for the world to achieve good health for all using science-based policies and programmes.
International Agency for Research on Cancer (IARC)
IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.
International Atomic Energy Agency (IAEA)
The IAEA’s aim is to help build Member States’ capacities to support them in establishing high-quality health care worldwide. Nuclear technology plays a key role in the diagnosis and treatment of cancer. Over the past six decades, the IAEA has gained strong technical expertise and experience in the delivery of nuclear medicine and radiotherapy technology to Member States, contributing to the fight against cancer. Its support ranges from nutrition interventions, cancer diagnosis and treatment, quality assurance for the use of radiation in medicine for safe and accurate treatment of conditions such as cancer. The IAEA also assists Member States with the coordination of research projects, expert guidance, imPACT Reviews, resource mobilization, the development of internationally harmonized guidelines and supporting the development of strategic documents, training, and knowledge exchange, safety and quality.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals.
International Geneva Welcome Centre (CAGI)
Founded by the Swiss Confederation and the Republic and Canton of Geneva, the International Geneva Welcome Centre is the single entry point for the support and integration of employees of International Geneva and their families, NGOs and visiting delegates.
Geneva Convention Bureau
State of Geneva
Union for International Cancer Control (UICC)
The Union for International Cancer Control's (UICC) rapidly increasing membership base of over 1200 organisations in 172 countries, represents the world’s major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners. In the last decade, we have reached millions of people with World Cancer Day, welcomed more than 15,000 delegates at our World Cancer Congresses, and launched four new organisations: the International Cancer Control Partnership, the McCabe Centre for Law & Cancer, City Cancer Challenge Foundation and the NCD Alliance.
IN PARTNERSHIP WITH
More info to be added soon.
Dutch Cancer Society (KWF)
The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members. The Dutch Cancer Society became full UICC member in 1982
French National Cancer Institute (INCa)
The French National Cancer Institute (INCa) was established under the French Public Health Act of August 9, 2004, as the State health and science agency specialised in cancer control. The Institute operates under the supervision of the French Ministry of Health and Solidarities and the French Ministry of Higher Education, Research and Innovation. It provides an integrated approach encompassing all cancer-control aspects (health, scientific, social and economic) and intervention areas (prevention, screening, care, research) to benefit patients and their relatives. The Institute is also a trusted source of evidence-based information, providing reliable advice on cancer control to government and guidance to health professionals and the community. The Institute drives the implementation of the French decennial strategy against cancer (2021-2030): it plays a pivotal role in maximising coordination amongst cancer control stakeholders to enhance impact.
Created in 2000, Gavi is an international organisation – a global Vaccine Alliance, bringing together public and private sectors with the shared goal of saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.
Geneva University Hospitals (HUG)
The HUG: Care, Teaching, and leading-edge Research The Geneva University Hospital (HUG) comprises eight public hospitals and two clinics. Theirs missions are to provide health care to the community in all medical specialties, to help train physicians and health professionals, and to conduct medical and clinical research. The HUG operate as a national reference centre for influenza, emerging viral infections, meningococcus, and transplant immunology, and are the national reference laboratory for histocompatibility. They are also a WHO Collaborating Centre in six areas, as well as Centres of Excellence in a number of sectors. The HUG treat 275,000 patients each year, with a capacity of 2,015 hospital beds, and employ 12.800 people. For more information on publications visit https://www.hug.ch/publications-hug www.hug.ch – firstname.lastname@example.org References: https://www.hug.ch/laboratoire-virologie/centre-national-reference-influenza-cnri https://www.hug.ch/centre-maladies-virales-emergentes http://www.meningo.ch/ https://www.hug.ch/nephrologie/unite-immunologie-transplantation https://www.hug.ch/en-bref https://www.hug.ch/centres
International Society of Paediatric Oncology (SIOP)
More info to be added soon
Nordic Cancer Union (NCU)
The Nordic Cancer Union (NCU) was founded in 1949. It is a collaborative body consisting of representatives from the Danish, Swedish, Finnish, Icelandic, Norwegian and Faroese cancer societies. NCU was established to enhance cooperation between the cancer societies in the Nordic countries. The strategies and priorities for NCU are stipulated for three-year periods by the NCU Board. They follow the rolling three-year presidencies hold by each cancer society in time. Currently, The Cancer Society of Finland holding the presidency for the term 2021 - 2023. The NCU Board meets three or four times annually. The meetings are a forum to facilitate discussion and information exchange about diverse activities at national levels. They also serve to decide on grants to be awarded by the NCU, both for scientific research (with participants from at least three Nordic countries) and for strategic projects (e.g., Covid-19 and cancer, Immigrants and cancer, Total cost of cancer) one million euro total each year. NCU is supporting Nordic cancer research collaboration through its research grants (bottom-up), while the strategic grants (top-down) are for supporting the strategic aims of the Nordic Cancer Union.
Norwegian Cancer Society
More info to be added soon.
Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, cheaply and effectively, in low- and middle-income countries. Our work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management. Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID Tools Accelerator. Unitaid is hosted by the World Health Organization.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. As of August 2021, thirty-two medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
Bristol Myers Squibb (BMS)
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Canadian Partnership Against Cancer (CPAC)
The Canadian Partnership Against Cancer is an independent organisation funded by the federal government to accelerate action on cancer control for all Canadians. The Partnership works with cancer experts, charitable organisations, governments, cancer agencies, national health organisations, patients, survivors and others to achieve their shared goal of a future in which fewer Canadians get cancer, fewer die from it and those living with the disease have a better quality of life. The Partnership’s work spans the cancer control continuum, from prevention and screening to research and supportive care. Their collaborative approach is mindful of the patient voice, and strives to be culturally responsive to the needs of local communities.
Cancer Research UK (CRUK)
Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.
Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include leadership in providing diagnostic solutions for cervical cancer screening, sexually transmitted infections, respiratory illnesses, and the virus that causes COVID-19; invention of the world’s first commercial 3D mammography system to fight breast cancer; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The company champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women.
US National Cancer Institute (NCI)
National Cancer Institute (NCI) is part of the NIH, one of 11 agencies that are part of the U.S. Department of Health and Human Services. NCI coordinates the U.S. National Cancer Program, which conducts and supports research, training, health information dissemination and other activities related to the cause, prevention, diagnosis, and treatment of cancer; cancer survivorship; and the continuing care of cancer patients and their families. NCI, Center for Global Health (NCI/CGH) supports the NCI mission by advancing global cancer research, and by coordinating NCI engagement in global cancer control. NCI/CGH has four strategic goals: (1) support innovative, impactful research that addresses key scientific issues in global cancer control and/or leverages unique scientific opportunities afforded by global collaboration; (2) support global cancer research training, particularly in low- and middle-income countries, that enables impactful global scientific collaboration; (3) promote the integration of current scientific knowledge in global cancer control; and (4) represent the NCI and promote its engagement with key partners in global cancer control.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, BeiGene is expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030.
China Anti-Cancer Association (CACA)
The Chinese Anti-Cancer Association (CACA), founded in 1984, has a mission to unite people involved in all branches of oncology and others with a similar interest in fighting cancer. CACA aims its utmost efforts at organizing scientific cooperation and conferences, promoting international non-governmental exchanges, conducting various training courses and seminars, fostering scientific, technological and medical personnel in the field of oncology, compiling and publishing academic periodicals, and mobilizing social forces to take part in popularization and dissemination of the knowledge of tumor prevention. Globally, the association is interested in organizing academic meetings with international colleagues in order to cultivate friendly ties with overseas oncology organizations and individuals. The Chinese Anti-Cancer Association has been a full UICC member since January 1997.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines, and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.
Prevent Cancer Foundation
More info to be added soon.
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
ABC Global Alliance
The ABC Global Alliance established in 2016 as an initiative of the European School of Oncology and now registered as a non-profit association in Portugal, is a multi-stakeholder platform for all those interested in collaborating on common projects relating to advanced breast cancer (ABC) with the aim to improve and extend the lives of women and men living with ABC in all countries worldwide and to fight for a cure. Website: www.abcglobalalliance.org E-mail: email@example.com Facebook: https://www.facebook.com/ABCGlobalAll Twitter: https://twitter.com/ABCGlobalAll LinkedIn: https://www.linkedin.com/company/abc-global-alliance/
American Society of Clinical Oncology (ASCO)
The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations with nearly 45,000 members in over 150 countries. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects. The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.
Healio enables you, the health care specialist, to select and tailor news and education to fit your daily practice of medicine. Designed as an in-depth specialty clinical information website, Healio features the industry’s best news reporting, dynamic multimedia, podcasts, question-and-answer columns, CME and other educational activities in a variety of formats, quick reference content, blogs, peer-reviewed journals and a wide range of popular medical book titles.
N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Recommended by 90,000 dermatologists worldwide, La Roche-Posay was created by a pharmacist in 1975 and is now present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water with antioxidant and soothing properties, also used at its Thermal Center, the first Dermatology Center in Europe. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.
Medicaid Cancer Foundation
The Medicaid Cancer Foundation (MCF) is a vehicle created by Medicaid to support cancer patients, promote cancer awareness and drive community cancer campaigns for undeserved populace in Nigeria. We provide support to guide people through the cancer experience, bring them together to fight cancer—and work for a world in which our fight is no longer necessary
Medicines Patent Pool (MPP)
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and 12 COVID-19 technologies. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs and SDC. https://medicinespatentpool.org/
Nigerian Cancer Society
On October 12, 1968, the Nigerian Cancer Society (NCS) was founded with the objective to assist in the development of facilities for diagnosis and treatment of cancer, to educate the public on ther problems of cancer, and to conduct research in all aspects of cancer. Since its founding, the society has expanded beyond the original founding town of Ibadan, and branches now exist in six geo-political zones of Nigeria. NCS’ first major successful publication was in 1982 with the book “Cancer in Nigeria-the proceedings of the NCS conference held in December 1979.” Since 1970, Nigerian Cancer Society has been associate UICC member.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the world’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1.1 trillion in the search for new treatments and cures, including $102.3 billion in 2021 alone. For information on how innovative medicines save lives, please visit: www.PhRMA.org
Rethink Breast Cancer
Our organization is focused on young women concerned about and affected by breast cancer. We educate young women about risk factors and how to be breast aware and "risk savvy" by organizing public heath forums, making documentary films and short videos, writing blog posts and engaging young people in the breast health conversation on social media. In addition, we are involved in trying to improve the experience for young women who find themselves diagnosed with breast cancer. We connect young women with breast cancer and create a community for them; we listen to their needs to identify gaps in care and then inspire them to work together and with us to create resources to address the unique needs of younger breast cancer patients and make changes to our health care system to improve the lives of other young women. We advocate for improved access to new innovative treatments in Canada. We want to make sure a young woman gets the right treatment at the ri
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.
The Lancet Oncology
The Lancet Oncology is the world-leading journal dedicated to clinical oncology research, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. As an internationally trusted source of clinical, public health, and global health knowledge, with an Impact Factor of 54.433 (2021 Journal Citation Reports®, Clarivate 2022), we have also fostered a reputation for hosting events for oncologists, cancer researchers, and policymakers, and convene many conferences, either independently or in collaboration with partners. Events include branded plenary lectures and sessions at conferences worldwide. We publish a range of article types that encompass all aspects of oncological medicine: Articles, Review, Policy Review, Personal View, Clinical Picture, Comment, Correspondence, News, and Perspectives. As part of our flagship advocacy programme, we also publish Series and Commissions (typically in partnership with societies, governments, NGOs, and academic centres) that aim to shape and drive positive change in clinical practice and health policy in areas of need in global oncology.
World Cancer Research Funds International (WCRF)
World Cancer Research Fund International (WCRF International) leads and unifies a global network of cancer charities dedicated to the prevention and control of cancer by means of healthy food and nutrition, physical activity and weight management. In particular, WCRF International plays a leading role in directing and supporting the research activities of the WCRF global network. Working with researchers, health professionals, policy makers and other health organisations throughout the world, we provide people with the information they need to make choices that can reduce their chances of developing cancer. WCRF's vision is that the their global network helps people make choices that reduce their chances of developing cancer. They were the first cancer charity to create awareness of the relationship between diet and cancer risk, to focus funding on research into diet and cancer prevention and to consolidate and interpret global research to create a practical message on cancer prevention. In 2005 WCRF became full UICC member.
Asociación Española Contra el Cáncer (AECC), Deloitte, ESCA CancerSupport, European Cancer Organisation (E.C.O.), Geneva Graduate Institute, Oncosuisse, Swiss Cancer League (SCL), Unicancer